Furthermore, growth factor inhibitors such as IL-6 inhibitors (tocilizumab) and MMP-2/-9 inhibitors (β-d mannuronic acid) have been designed to affect tumor progression, invasion, and metastasis by inhibition of chronic immune response and prevention of remodeling ECM [82,87]. Here, MMP2 is linked to neoplasm.